Nilotinib

Drug Profile

Nilotinib

Alternative Names: AMN-107; Tasigna; XS 003

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Dana-Farber Cancer Institute; Hospital for Special Surgery; Novartis Pharmaceuticals Corporation; University Health Network of Toronto
  • Class Antineoplastics; Benzamides; Imidazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Malignant melanoma
  • Phase I/II Acute myeloid leukaemia
  • No development reported Gastrointestinal stromal tumours; Systemic scleroderma
  • Discontinued Eosinophilia

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse event data from a phase II NILSw trial in Chronic myeloid leukemia (Second-line therapy) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Efficacy data from a phase II trial in Chronic myeloid leukemia (Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 17 Jun 2016 No development reported - Phase-II for Systemic scleroderma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top